EGFR and exanthem: The most common reaction reported is skin rash,1 which appears in 43–85% of patients treated with epidermal growth factor receptor inhibitors (EGFRI)s.5 This rash follows a typical, chronological pattern that peaks in severity during the first 1–2 weeks.6–7 Although it is not associated with death, reports of serious morbidity have been identified.27 In the current absence of consistent clinical trials, patients are therefore advised to use mild skin care and photoprotection.16–28